ClinicalTrials.Veeva
Menu

Find clinical trials for Acute Myeloid Leukemia (AML) in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Acute Myeloid Leukemia
Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Cleveland, OH, USA:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Cleveland, Ohio, United States and 125 other locations

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Cleveland, Ohio, United States and 164 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...

Enrolling
Relapsed Adult AML
Leukemia, Myeloid, Acute
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Cleveland, Ohio, United States and 33 other locations

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA)

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...

Active, not recruiting
AML
Acute Myelogenous Leukemia
Drug: Iomab-B
Drug: Conventional Care

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Cleveland, Ohio, United States and 23 other locations

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

to venetoclax + azacitidine in adults recently diagnosed with AML who are unable to be treated with intensive chemotherapy.Participants will...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Pevonedistat
Drug: Venetoclax

Phase 2

Takeda
Takeda

Cleveland, Ohio, United States and 56 other locations

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomiz...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Cleveland, Ohio, United States and 43 other locations

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human ...

Enrolling
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: Mylotarg
Biological: VOR33

Phase 1, Phase 2

Vor Biopharma

Cleveland, Ohio, United States and 14 other locations

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy (TRILLIUM)

). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligible for intensive chemotherapy....

Enrolling
Acute Myeloid Leukemia
Drug: Venetoclax
Drug: Tagraxofusp

Phase 2

Stemline Therapeutics
Stemline Therapeutics

Cleveland, Ohio, United States and 35 other locations

A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (A...

Enrolling
Leukemia
Drug: GDX012
Drug: Chemotherapy Agents

Phase 1, Phase 2

Takeda
Takeda

Cleveland, Ohio, United States and 13 other locations

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SG...

Enrolling
Acute Myeloid Leukemia
High-Risk and Very High-Risk Myelodysplastic Syndromes
Drug: SGR-2921

Phase 1

Schrödinger, Inc.

Cleveland, Ohio, United States and 11 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems